BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nölting S, Grossman A, Pacak K. Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. Exp Clin Endocrinol Diabetes 2019;127:117-28. [PMID: 30235495 DOI: 10.1055/a-0715-1888] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Cassell III AK, Bague AH. Current trend in the diagnosis and management of malignant pheochromocytoma: Clinical and prognostic factors. World J Meta-Anal 2020; 8(5): 375-382 [DOI: 10.13105/wjma.v8.i5.375] [Reference Citation Analysis]
2 Goncalves J, Lussey-Lepoutre C, Favier J, Gimenez-Roqueplo AP, Castro-Vega LJ. Emerging molecular markers of metastatic pheochromocytomas and paragangliomas. Ann Endocrinol (Paris) 2019;80:159-62. [PMID: 31053249 DOI: 10.1016/j.ando.2019.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Jaiswal SK, Sarathi V, Memon SS, Garg R, Malhotra G, Verma P, Shah R, Sehemby MK, Patil VA, Jadhav S, Lila AR, Shah NS, Bandgar TR. 177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma. Endocr Connect 2020;9:864-73. [PMID: 32784267 DOI: 10.1530/EC-20-0292] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
4 Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, Pacak K. Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers (Basel) 2019;11:E1505. [PMID: 31597347 DOI: 10.3390/cancers11101505] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 13.7] [Reference Citation Analysis]
5 Zhang H, Ge F, Shui X, Xiang Y, Wang X, Liao C, Wang J. NIX protein enhances antioxidant capacity of and reduces the apoptosis induced by HSP90 inhibitor luminespib/NVP-AUY922 in PC12 cells. Cell Stress Chaperones 2021;26:495-504. [PMID: 33629253 DOI: 10.1007/s12192-021-01193-6] [Reference Citation Analysis]
6 Taïeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer 2019;26:R627-52. [PMID: 31561209 DOI: 10.1530/ERC-19-0165] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 12.5] [Reference Citation Analysis]
7 Casey R, Neumann HPH, Maher ER. Genetic stratification of inherited and sporadic phaeochromocytoma and paraganglioma: implications for precision medicine. Hum Mol Genet 2020;29:R128-37. [PMID: 33059362 DOI: 10.1093/hmg/ddaa201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu Y, Pang Y, Zhu B, Uher O, Caisova V, Huynh TT, Taieb D, Hadrava Vanova K, Ghayee HK, Neuzil J, Levine M, Yang C, Pacak K. Therapeutic Targeting of SDHB-Mutated Pheochromocytoma/Paraganglioma with Pharmacologic Ascorbic Acid. Clin Cancer Res 2020;26:3868-80. [PMID: 32152203 DOI: 10.1158/1078-0432.CCR-19-2335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Gao S, Liu L, Li Z, Pang Y, Shi J, Zhu F. Seven Novel Genes Related to Cell Proliferation and Migration of VHL-Mutated Pheochromocytoma. Front Endocrinol (Lausanne) 2021;12:598656. [PMID: 33828526 DOI: 10.3389/fendo.2021.598656] [Reference Citation Analysis]
10 Jhawar S, Arakawa Y, Kumar S, Varghese D, Kim YS, Roper N, Elloumi F, Pommier Y, Pacak K, Del Rivero J. New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications. Cancers (Basel) 2022;14:594. [PMID: 35158861 DOI: 10.3390/cancers14030594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tella SH, Jha A, Taïeb D, Horvath KA, Pacak K. Comprehensive review of evaluation and management of cardiac paragangliomas. Heart 2020;106:1202-10. [PMID: 32444502 DOI: 10.1136/heartjnl-2020-316540] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Pacak K, Eisenhofer G, Tischler AS. Phaeochromocytoma - advances through science, collaboration and spreading the word. Nat Rev Endocrinol 2020;16:621-2. [PMID: 32934348 DOI: 10.1038/s41574-020-00413-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Drechsel A, Helm J, Ehrlich H, Pantovic S, Bornstein SR, Bechmann N. Anti-Tumor Activity vs. Normal Cell Toxicity: Therapeutic Potential of the Bromotyrosines Aerothionin and Homoaerothionin In Vitro. Mar Drugs 2020;18:E236. [PMID: 32369901 DOI: 10.3390/md18050236] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
14 Rai SK, Bril F, Hatch HM, Xu Y, Shelton L, Kalavalapalli S, Click A, Lee D, Beecher C, Kirby A, Kong K, Trevino J, Jha A, Jatav S, Kriti K, Luthra S, Garrett TJ, Guingab-Cagmat J, Plant D, Bose P, Cusi K, Hromas RA, Tischler AS, Powers JF, Gupta P, Bibb J, Beuschlein F, Robledo M, Calsina B, Timmers H, Taieb D, Kroiss M, Richter S, Langton K, Eisenhofer G, Bergeron R Jr, Pacak K, Tevosian SG, Ghayee HK. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. Metabolism 2020;110:154297. [PMID: 32562798 DOI: 10.1016/j.metabol.2020.154297] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 De Filpo G, Maggi M, Mannelli M, Canu L. Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview. J Endocrinol Invest 2021;44:15-25. [PMID: 32602077 DOI: 10.1007/s40618-020-01344-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
16 Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B, William D, Gieldon L, Maurer J, Spöttl G, Rank P, Knösel T, Orth M, Ziegler CG, Aristizabal Prada ET, Rubinstein G, Fassnacht M, Spitzweg C, Grossman AB, Pacak K, Beuschlein F, Bornstein SR, Eisenhofer G, Auernhammer CJ, Reincke M, Nölting S. Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology 2019;160:2600-17. [PMID: 31322702 DOI: 10.1210/en.2019-00410] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
17 Pozza C, Sesti F, Di Dato C, Sbardella E, Pofi R, Schiavi F, Bonifacio V, Isidori AM, Faggiano A, Lenzi A, Giannetta E. A Novel MAX Gene Mutation Variant in a Patient With Multiple and "Composite" Neuroendocrine-Neuroblastic Tumors. Front Endocrinol (Lausanne) 2020;11:234. [PMID: 32508744 DOI: 10.3389/fendo.2020.00234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
18 Puliani G, Sesti F, Feola T, Di Leo N, Polti G, Verrico M, Modica R, Colao A, Lenzi A, Isidori AM, Cantisani V, Giannetta E, Faggiano A. Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family. J Clin Med 2020;9:E588. [PMID: 32098148 DOI: 10.3390/jcm9020588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Flores SK, Estrada-Zuniga CM, Thallapureddy K, Armaiz-Peña G, Dahia PLM. Insights into Mechanisms of Pheochromocytomas and Paragangliomas Driven by Known or New Genetic Drivers. Cancers (Basel) 2021;13:4602. [PMID: 34572828 DOI: 10.3390/cancers13184602] [Reference Citation Analysis]